DekaBank Deutsche Girozentrale boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 17.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,090 shares of the company’s stock after purchasing an additional 2,855 shares during the period. DekaBank Deutsche Girozentrale’s holdings in IDEXX Laboratories were worth $3,032,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in shares of IDEXX Laboratories by 10.5% during the second quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock valued at $1,146,142,000 after acquiring an additional 673,347 shares during the period. Advisors Capital Management LLC bought a new stake in IDEXX Laboratories in the third quarter worth approximately $262,000. Cipher Capital LP bought a new stake in IDEXX Laboratories in the second quarter worth approximately $2,284,000. American Century Companies Inc. grew its position in IDEXX Laboratories by 131.7% in the second quarter. American Century Companies Inc. now owns 480,978 shares of the company’s stock worth $77,639,000 after acquiring an additional 273,398 shares in the last quarter. Finally, Pitcairn Co. grew its position in IDEXX Laboratories by 21.8% in the second quarter. Pitcairn Co. now owns 6,977 shares of the company’s stock worth $1,126,000 after acquiring an additional 1,249 shares in the last quarter. 86.80% of the stock is owned by institutional investors and hedge funds.
Shares of IDEXX Laboratories, Inc. (NASDAQ IDXX) traded down $0.21 during trading on Thursday, hitting $159.78. 417,485 shares of the company were exchanged, compared to its average volume of 702,380. The firm has a market cap of $13,960.00, a PE ratio of 53.80, a P/E/G ratio of 2.42 and a beta of 0.42. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48. IDEXX Laboratories, Inc. has a 1-year low of $113.92 and a 1-year high of $173.01.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.05. The firm had revenue of $492.00 million during the quarter, compared to analysts’ expectations of $492.94 million. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.62 EPS. equities analysts predict that IDEXX Laboratories, Inc. will post 3.24 EPS for the current year.
IDXX has been the subject of several recent analyst reports. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective for the company in a report on Tuesday, October 24th. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Canaccord Genuity reissued a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a report on Friday, October 6th. Finally, Bank of America raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target for the company in a report on Wednesday, August 23rd. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. IDEXX Laboratories has an average rating of “Hold” and a consensus price target of $173.67.
In related news, insider Giovani Twigge sold 2,000 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $156.07, for a total transaction of $312,140.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $148.35, for a total transaction of $2,670,300.00. Following the transaction, the chief executive officer now directly owns 1,064,573 shares in the company, valued at approximately $157,929,404.55. The disclosure for this sale can be found here. Insiders sold a total of 110,000 shares of company stock worth $16,686,200 in the last ninety days. Insiders own 2.77% of the company’s stock.
WARNING: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2017/12/07/dekabank-deutsche-girozentrale-purchases-2855-shares-of-idexx-laboratories-inc-idxx.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.